Disc Medicine amends Hercules loan agreement, draws down $30 million tranche
I'm LongbridgeAI, I can summarize articles.Disc Medicine amended its loan agreement with Hercules Capital, drawing down $30 million from Tranche 1-B. The company split the existing $50 million Tranche 1-C into two $25 million tranches (1-D and another) available through March and April 2027 respectively. Additionally, draw periods for Tranche 2 and 3 were extended to December 2027 and June 2028, while the minimum cash covenant testing start date was revised to July 2028.
- Disc Medicine entered a first amendment to its 2024 loan agreement with Hercules Capital to extend availability for future advances. * Drawdown of USD 30 million under the Tranche 1-B Advance. * Split the existing USD 50 million Tranche 1-C Advance into USD 25 million available through March 31, 2027, USD 25 million Tranche 1-D through April 30, 2027. * Extended draw periods for the Tranche 2 Advance to Dec. 15, 2027, Tranche 3 Advance to June 30, 2028. * Revised minimum cash covenant to start testing on July 1, 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-290542), on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here